Kristin Sherman Appointed CFO of Growing Biomarketing Company
INDIANAPOLIS, INDIANA, August 17, 2016 (Newswire.com) - VMS BioMarketing, a company dedicated to helping patients successfully start and stay on therapies, announced today the appointment of Kristin Sherman as chief financial officer. In her new role, Sherman will oversee finance, data and analytics, and human resources. She is looking forward to exploring partnership and acquisition opportunities for VMS to expand its impact on improving patient outcomes.
Across her tenure as a financial executive, Sherman has managed diverse and complex business environments. She has successfully built and restructured organizations, set strategy and leveraged limited resources in entrepreneurial organizations. In addition, she has worked in private and public life science companies, held domestic and international roles, and been involved in a wide range of therapeutic areas.
"I'm excited to join a firm dedicated to connecting nurses and patients, empowering people, and improving lives."
Kristin Sherman, Chief financial officer
Sherman comes to VMS BioMarketing from Calibrium, LLC, where she spent three years as the company’s chief financial officer. In her role, Sherman provided finance, legal and human resources oversight including coordination of the company’s initial financing, management of strategic partnerships with universities and pharmaceutical companies, and oversight of the final sale of the company to Novo Nordisk.
Immediately prior to Calibrium, Sherman held similar roles for two additional biotech start-ups including Marcadia Biotech until its acquisition by Roche in 2010 and AgeneBio, which focused on Alzheimer’s disease. In addition, Sherman served as the treasurer and vice president of finance for Guidant Corporation during the sale of Guidant to Abbott and Boston Scientific. She also held a variety of management positions including serving as Guidant’s first finance director for emerging markets. Sherman began her career in various finance positions with Eli Lilly and Company and was assistant treasurer during Guidant’s spin-off from Lilly.
“I am thrilled to join the VMS team and to be part of a company committed to enhancing the quality of life for those living with chronic illness,” said Sherman. “I’m excited to join a firm dedicated to connecting nurses and patients, empowering people, and improving lives. I’ve spent my career in the life sciences industry, and I look forward to focusing on supporting patients through high-tech and high-touch solutions in this next stage of my career,” she said.
The CFO role is a new position at VMS BioMarketing, created to continue to accelerate high growth at the company during an era when the demand for patient support services is exploding.
“Kristin’s in-depth knowledge of finance, strategy and management, and her 23 years of financial and pharmaceutical experience will greatly benefit VMS,” said Andrea Heslin Smiley, VMS president and chief executive officer. “We can’t wait to begin utilizing her insightful approaches to finance and business development as VMS continues to grow and expand its scope toward empowering and bettering the lives of patients.”
Sherman earned her Bachelor of Arts degree in economics from DePauw University in Greencastle, Indiana. She has an MBA from the Tuck School of Business at Dartmouth College in Hanover, New Hampshire, where she achieved distinction as a Tuck Scholar. Sherman is the current treasurer of the Community Health Network Board as well as chair of the Community Health Network Board’s Finance, Audit and Compliance Committee.
About VMS BioMarketing:
VMS BioMarketing is a leading healthcare education company focused on empowering patients and healthcare providers through education, training, and ongoing health coaching. For more than 20 years, VMS has been dedicated to enabling Nurse Educators to provide the personalized support necessary to help patients successfully start and stay on therapy. VMS clients include the world’s leading pharmaceutical and biotechnology companies.
Source: VMS BioMarketing
